FindTrial
Sign In

Mechanism of Lianshi Jianpi Formula in regulating metabolic-associated fatty liver disease via PRCP-mediated melanocortin system

Mechanisms of Lianshi Jianpi Formula in Regulating Metabolic-Associated Fatty Liver Disease via PRCP-Mediated Melanocortin System

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001012
Enrollment
Unknown
Registered
2025-05-19
Start date
2025-05-21
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic-Associated Fatty Liver Disease

Interventions

Control group:Lifestyle Intervention
Treatment group:Lianshi Jianpi Formula and Lifestyle Intervention

Sponsors

People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Meeting the diagnostic criteria for metabolic-associated fatty liver disease (MAFLD) in overweight/obese subgroups with BMI =23 kg/m²; (2)Conforming to Traditional Chinese Medicine diagnostic criteria for "Internal Dampness-Turbidity Syndrome" ; (3)Age between 18 and 65 years (inclusive); (4)No participation in any drug clinical trials within 3 months prior to enrollment; (5)Willingness to provide written informed consent.

Exclusion criteria

Exclusion criteria: (1)Patients with a history of diabetes for more than 5 years and/or those taking hypoglycemic medications; (2)Patients with hepatic steatosis caused by other etiologies (e.g. alcohol genetic disorders); (3)Patients with secondary obesity due to medications endocrine disorders or other known causes; (4)Age 65 years; (5)Patients with a history of severe gastrointestinal diseases; (6)Special populations including pregnant or lactating women and individuals with psychiatric disorders; (7)Patients with comorbidities such as malignancies active infections immune system disorders hematopoietic diseases or other severe systemic conditions.

Design outcomes

Primary

MeasureTime frame
Prolylcarboxypeptidase (PRCP);Melanocortin receptor-4(MC4R);Fibrosis-4 index;Traditional Chinese Medicine Syndrome Score;Liver ultrasound;liver function;—

Secondary

MeasureTime frame
Homeostatic Model Assessment of Insulin Resistance(HOMA-IR);Fasting blood glucose;renal function;hypersensitive C-reactive protein;glycosylated hemoglobin;General examination (body temperature heart rate respiration blood pressure);urinalysis;Serum Lipid Levels(TC\TG\LDL-C\HDL-C);Fasting insulin;Complete Blood Count;—

Countries

China

Contacts

Public ContactMingqian Jiang

People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine

JMQian1130@hotmail.com18850351500

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026